Pancreatic tumours: Molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis

British Journal of Cancer

Volumn 84, Issue 2, 2001, Pages 253-262

  Moore, P S ^a   Orlandini, S ^a   Zamboni, G ^a   Capelli, P ^a   Rigaud, G ^a   Falconi, M ^a   Bassi, C ^a   Lemoine, N R ^b   Scarpa, A ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Acinar cancer; Allelotyping; Ampulla of Vater cancer; Carcinoma; DPC4 Smad4; Endocrine tumour; Intraductal papillary mucinous tumour; K ras; Microsatellites; P16; P53; Pancreas; Solid pseudopapillary tumour

Indexed keywords

PROTEIN P16; PROTEIN P53; SMAD PROTEIN;

ACINAR CELL; ADOLESCENT; ALLELE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; GENE LOSS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; ONCOGENE K RAS; PANCREAS CARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA, MUCINOUS; AMPULLA OF VATER; BASE SEQUENCE; CARCINOMA, ACINAR CELL; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; COMMON BILE DUCT NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; ENDOCRINE GLAND NEOPLASMS; ENDOCRINE GLANDS; EXOCRINE GLANDS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MUTATION; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RAS PROTEINS; SMAD4 PROTEIN; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035156850     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1567     Document Type: Article

References (55)

1. Chromosome 7q allelic losses in pancreatic carcinoma
2. APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis
3. Cancers of the papilla of Vater: Mutator phenotype is associated with good prognosis
4. Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer
5. CDKN2A variants in a population-based sample of Queensland families with melanoma
6. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
7. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
8. K-ras orcogene mutations indicate malignancy in cystic tumors of the pancreas
9. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas
10. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
11. Pancreatic endocrine tumours: Evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p
12. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
13. Analysis of K-ras gene mutations in rare pancreatic and ampullary tumours
14. Immunohistochemical p161NK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies
15. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
16. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma
17. Methylation-specific PCR: A novel PCR assay for methylation status of Clog islands
18. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation
19. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
20. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas
21. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer
22. p53 and K-RAS alterations in pancreatic epithelial cell lesions
23. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases
24. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas
25. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients
26. Papillary cystic tumors of the pancreas: Assessment of malignant potential by analysis of progesterone receptor, flow cytometry, and ras oncogene mutation
27. Ki-ras oncogene activation in preinvasive pancreatic cancer
28. Two novel polymorphisms, c 1086T>C and c1798C>T, in the MADH4/DPC4 gene
29. A novel germline mutation, P48T, in the CDKN2A/p16 gene in a patient with pancreatic carcinoma
30. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: An analysis of p16/MTSI tumor suppressor gene inactivation
31. Frequent codeletion of p 16/MTS1 and p 15/MTS2 and genetic alterations in pl6/MTS1 in pancreatic tumors
32. Immunohistochemical survey of p161NK4A expression in normal human adult and infant tissues
33. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
34. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
35. p16 proteins from melanoma-prone families are deficient in binding to Cdk4
36. Tumor-suppressive pathways in pancreatic carcinoma
37. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas
38. Pancreatic adenocarcinomas frequently show p53 gene mutations
39. Neoplasia of the ampulla of Vater, Ki-ras and p53 mutations
40. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences
41. Ras-family gene mutations in neoplasia of the ampulla of Vaten Int J Cancer
42. Chromosome 17p loss and prognosis of cancer of papilla of Vater
43. Abrogation of the Rb/p 16 tumor-suppressive pathway in virtually all pancreatic carcinomas
44. Intraductal papillary-mucinous pancreatic tumors are phenotypically, genetically and behaviorally distinct growths. An analysis of tumor cell phenotype, K-ras and p53 gene mutations
45. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers
46. Only wild-type c-Ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas
47. Hypermethylation of multiple genes in pancreatic adenocarcinoma
48. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells
49. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression
50. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation
51. Expression of progesterone receptors in solid-cystic tumour of the pancreas: A clinicopathological and immunohistochemical study of ten cases
52. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas
53. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck